S-1 + CPT-11（每4 - 5周一次）联合化疗用于转移性胃癌

[Combination chemotherapy of S-1 +CPT-11 (q 4-5 w) for metastatic gastric cancer].

作者信息

Sugimoto Naotoshi, Narahara Hiroyuki

机构信息

Dept. of Clinical Oncology Graduate School of Biomedical Sciences, Hiroshima University, Japan.

出版信息

Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:79-82. doi: 10.2217/14750708.3.1.79.

DOI:10.2217/14750708.3.1.79

PMID:16897977

Abstract

The effectiveness of systemic chemotherapy for metastatic gastric cancer has already been established. However, a standard chemotherapy still remains uncertain. New agents such as S-1, CPT-11 and taxanes are markedly improving the response rates for gastric cancer. Including these new drugs, several randomized phase III trials are ongoing in Japan. In the near future, the candidate for standard regimen to treat gastric cancer will be reported. In this article, we described the current state of S-1 +CPT-11 combination chemotherapy for gastric cancer. Among various CPT-11 based chemotherapy, S-1 +CPT-11 appears to be the most effective and less toxic treatment.

摘要

全身化疗对转移性胃癌的有效性已经得到证实。然而，标准化疗方案仍不明确。诸如S-1、伊立替康和紫杉烷等新型药物显著提高了胃癌的缓解率。包括这些新药在内，日本正在进行几项III期随机试验。在不久的将来，有望报道治疗胃癌的标准方案。在本文中，我们描述了S-1 +伊立替康联合化疗治疗胃癌的现状。在各种基于伊立替康的化疗中，S-1 +伊立替康似乎是最有效且毒性较小的治疗方法。